Loading…

Factor VIII and IX assays for post‐infusion monitoring in hemophilia patients: Guidelines from the French BIMHO group (GFHT)

Replacement therapy with plasma‐derived or recombinant FVIII and FIX (pdFVIII/pdFIX or rFVIII/rFIX) concentrates is the standard of treatment in patients with haemophilia A and B, respectively. Measurement of factor VIII (FVIII:C) or factor IX (FIX:C) levels can be done by one‐stage clotting assay (...

Full description

Saved in:
Bibliographic Details
Published in:European journal of haematology 2020-08, Vol.105 (2), p.103-115
Main Authors: Jeanpierre, Emmanuelle, Pouplard, Claire, Lasne, Dominique, Le Cam Duchez, Véronique, Eschwege, Valérie, Flaujac, Claire, Galinat, Hubert, Harzallah, Ines, Proulle, Valérie, Smahi, Motalib, Sobas, Frédéric, Stepina, Nataliia, Toulon, Pierre, Voisin, Sophie, Ternisien, Catherine, Nougier, Christophe, Gelas, Martine Alhenc, Biron, Christine, Blanc‐Jouvan, Florence, Bourgerette, Evelyne, Bulabois, Benedicte, Comio, Emilie, Donnard, Magali, Duchemin, Jerôme, Faure, Anne‐Camille, Grand, François, Grunebaum, Lelia, Guicheteau, Maryse, Guerrero, Felipe, Hezard, Nathalie, Hurtaud, Marie‐Françoise, Nedelec Gac, Fabienne, De Maistre, Emmanuel, Marlu, Raphael, Mourey, Guillaume, Munier, Perrine, Pineau‐Vincent, Fabienne, Raffenot, Didier, Repesse, Yohan, Ryman, Anne, Sattler, Laurent, Sauguet, Pauline, Serre‐Sapin, Anne‐Francoise, Stepanian, Alain, Szymezak, Jean, Toussaint‐Hacquart, Marie, Tuffigo, Marie, Voyer, Annelise
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Replacement therapy with plasma‐derived or recombinant FVIII and FIX (pdFVIII/pdFIX or rFVIII/rFIX) concentrates is the standard of treatment in patients with haemophilia A and B, respectively. Measurement of factor VIII (FVIII:C) or factor IX (FIX:C) levels can be done by one‐stage clotting assay (OSA) or chromogenic substrate assay (CSA). The French study group on the Biology of Hemorrhagic Diseases (a collaborative group of the GFHT and MHEMO network) presents a literature review and proposals for the monitoring of FVIII:C and FIX:C levels in treated haemophilia A and B patients, respectively. The use of CSA is recommended for the monitoring of patients treated with pdFVIII or rFVIII including extended half‐life (EHL) rFVIII. Except for rFVIII‐Fc, great caution is required when measuring FVIII:C levels by OSA in patients substituted by EHL‐rFVIII. The OSA is recommended for the monitoring of patients treated with pdFIX or rFIX. Large discordances in the FIX:C levels measured for extended half‐life rFIX (EHL‐rFIX), depending on the method and reagents used, must lead to great attention when OSA is used for measuring FIX:C levels in patients substituted by EHL‐rFIX. Data of most of recent studies, obtained with spiked plasmas, deserve to be confirmed in plasma samples of treated patients.
ISSN:0902-4441
1600-0609
DOI:10.1111/ejh.13423